Octreotide


Generic Medicine Info
Special Precautions
Patient with insulinomas, diabetes mellitus; heart failure, conditions which cause excessive fluid loss; history of vitamin B12 deprivation; liver cirrhosis. Renal and hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor hepatic function; serum GH and IGF-1 (in acromegaly); urinary 5-hydroxyindole acetic acid (5-HIAA), plasma serotonin and plasma substance P (in carcinoid tumours); plasma VIP (in VIPomas). Assess for signs of tumour expansion (e.g. visual field defects). Chronic treatment: Monitor thyroid function (e.g. TSH, total and/or free T4) at baseline and periodically; cardiac function (e.g. ECG, heart rate), vitamin B12 levels; blood glucose and glycaemic control (in diabetic patients); zinc level (in patients with excessive fluid loss maintained on TPN). Perform gallbladder monitoring and ultrasound examination as necessary.
Adverse Reactions
Significant: Bradycardia, conduction abnormalities, arrhythmia; impaired gallbladder function causing cholelithiasis and its related complications (e.g. cholecystitis, cholangitis, pancreatitis); hypoglycaemia, hyperglycaemia, hypothyroidism. Blood and lymphatic system disorders: Hyperbilirubinaemia. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain, abdominal bloating, constipation, flatulence, dyspepsia, loose stools, steatorrhoea, discolourations of faeces. General disorders and administration site conditions: Injection site pain, asthenia. Investigations: Elevated transaminases; decreased TSH, total and free T4. Metabolism and nutrition disorders: Anorexia, impaired glucose tolerance. Nervous system disorders: Headache, dizziness. Respiratory, thoracic and mediastinal disorders: Dyspnoea. Skin and subcutaneous tissue disorders: Pruritus, rash, alopecia.
Drug Interactions
May impair insulin secretion; dosage adjustments of insulins and other antidiabetic medications may be required. Decreased intestinal absorption of ciclosporin. Delayed intestinal absorption of cimetidine. Increased bioavailability of bromocriptine. May cause additive bradycardia; dose adjustment of β-blockers, Ca channel blockers, or drugs that control fluid and electrolyte balance may be necessary.
CIMS Class
Other Gastrointestinal Drugs / Trophic Hormones & Related Synthetic Drugs
ATC Classification
H01CB02 - octreotide ; Belongs to the class of antigrowth hormone. Used in hypothalamic hormone preparations.
Disclaimer: This information is independently developed by CIMS based on octreotide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in